Pure Global
NCT01631279

A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors

A Phase I/II, Multi-Center, Open-Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR610 Given Weekly in Subjects With Solid Tumors
Proacta, Incorporated·Early Phase 1·ClinicalTrials.gov·drugTerminated
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Unspecified Adult Solid Tumor, Protocol Specific
Drug/Device/Intervention
PR610
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Proacta, Incorporated
Location
Scottsdale,Sacramento,Chicago,San Antonio,Auckland,Waikato, New Zealand,United States of America
Timeline & enrollment
Phase
Early Phase 1
Start date
Aug 01, 2012
End date
Aug 01, 2015
Enrollment
33 participants
Primary outcome

Determine the Maximum Tolerated Dose (MTD) of PR610 for Both a 1-hour and a 24-hour Weekly IV Infusion,Determine the Dose-Limiting Toxicity (DLT) of PR610 for Both a 1-hour and a 24-hour Weekly IV Infusion

Summary

The purpose of this study is to determine the Maximum Tolerated Dose and the Dose-Limiting
 Toxicity of the drug to further evaluate safety and antitumor activity.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm, without specification of siteMalignant neoplasm, primary site unspecifiedCarcinoma in situ of other and unspecified genital organsMalignant neoplasm: Connective and soft tissue, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01631279
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01631279 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by Proacta, Incorporated and is currently Terminated. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 33 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.